Press "Enter" to skip to content

Regeneron study shows drug‑antibody combo eradicates tumors in mice

A team of scientists at Regeneron Pharmaceuticals has reported that a two‑part treatment—combining the antibody‑drug conjugate Enhertu with an experimental bispecific antibody—completely eliminated tumors in laboratory mice and induced an immune response capable of rejecting re‑introduced cancer cells. The findings, published in Nature Communications, detail experiments conducted in genetically engineered mouse models of breast and colorectal cancer that express the human CD28 protein on T cells.

Study design and therapeutic agents

The investigators used mice whose tumor cells were modified to display the molecular targets required for the therapy. Enhertu, also known as trastuzumab deruxtecan, is an approved drug that couples an anti‑HER2 antibody with a cytotoxic payload. It delivers the cell‑killing compound directly to HER2‑expressing cancer cells and is already used in certain breast, stomach and other HER2‑positive tumors.

The experimental component of the regimen is a bispecific antibody engineered to bind two distinct proteins simultaneously: one on the surface of the tumor cell and CD28 on T cells. By engaging CD28, the antibody is intended to provide a co‑stimulatory signal that amplifies T‑cell activation against the cancer.

Efficacy in breast cancer models

In the first set of experiments, mice bearing a HER2‑positive breast cancer were treated with Enhertu alone, at doses ranging up to the highest level tested in the study. Even at that maximum dose, fewer than half of the animals achieved a complete tumor response. When the same mice received the bispecific antibody in addition to Enhertu, all nine animals in the combination group experienced full tumor eradication, a result the authors describe as a complete response across the cohort.

To evaluate the durability of the response, the researchers waited at least four weeks after the tumors disappeared and then re‑introduced the identical breast cancer cells into the cured mice without providing any further therapy. The previously treated animals rejected the new cancer cells, indicating that the combination had generated a memory immune response capable of recognizing and eliminating the same tumor upon re‑exposure.

Interestingly, during the same observation period, a separate colorectal tumor emerged in the same mice. Although those colorectal cancer cells also expressed HER2, the animals did not reject them automatically, suggesting that the immune memory was directed not only at HER2 but also at additional tumor‑specific features present in the original breast cancer.

Immune mechanisms and broader implications

The study identified CD8⁺ T cells as essential mediators of the therapeutic effect. When the researchers depleted CD8⁺ T cells in the mice, the combination treatment lost its efficacy entirely, underscoring the pivotal role of these cytotoxic lymphocytes. Flow‑cytometric analysis of tumor‑infiltrating lymphocytes revealed an increased proportion of activated T cells and a broader repertoire of T‑cell receptors, a finding that could explain the ability of the immune system to recognize multiple tumor antigens beyond HER2.

Beyond the primary breast cancer model, the authors explored additional antibody‑drug pairings. An antibody that targets epidermal growth factor receptor (EGFR) was combined with Enhertu in a breast cancer model that was relatively resistant to Enhertu alone. This regimen achieved tumor rejection in approximately 75 % of the mice, demonstrating that the bispecific approach can enhance the activity of Enhertu against harder‑to‑treat cancers. The EGFR‑targeting antibody is already undergoing early‑phase clinical evaluation (phase 1/2).

In a separate colorectal cancer experiment, the EGFR‑targeting bispecific antibody was paired with the chemotherapy agent 5‑fluorouracil. While each agent alone had minimal impact on tumor growth, the combination slowed tumor progression markedly. The anti‑tumor activity in this setting required both CD8⁺ T cells and natural killer (NK) cells; removal of either cell type reduced the therapeutic benefit, and loss of both cell populations abolished it.

Limitations and next steps

The authors caution that mouse models do not capture the full spectrum of potential side effects in humans, and they emphasize that the safety and efficacy of the combination must be validated in clinical trials. Regeneron funded the entire research program, and all authors are current or former Regeneron employees who have filed patent applications related to the bispecific antibody technology.

If the promising preclinical results translate to patients, the strategy could expand the therapeutic reach of existing antibody‑drug conjugates like Enhertu, turning them into platforms that actively recruit the patient’s own immune system to sustain tumor control after the drug is cleared.

The study adds to a growing body of evidence that bispecific antibodies, when paired with targeted cytotoxic agents, can convert a primarily cell‑killing approach into a durable immunological attack. Future clinical investigations will need to address dosing, potential immune‑related toxicities, and the identification of biomarkers that predict which patients are most likely to benefit from such combination regimens.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *